Poz.com, January 21, 2021
On January 21, the Food and Drug Administration (FDA) in the USA approved the first complete injectable HIV treatment regimen that does not require daily pills.
Cabenuva, from ViiV Healthcare, is administered only once a month. It is approved for people with an undetectable viral load on their current therapy who wish to switch to a long-acting regimen.
Cabenuva consists of an extended-release formulation of the integrase inhibitor cabotegravir plus an injectable version of Janssen’s non-nucleoside reverse transcriptase inhibitor rilpivirine (sold in pill form as Edurant).